(WGS) GeneDx Holdings - Overview
Stock: Genetic Testing, Whole Exome Sequencing, Whole Genome Sequencing, AI Platform
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 90.2% |
| Relative Tail Risk | -20.5% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.76 |
| Alpha | 2.58 |
| Character TTM | |
|---|---|
| Beta | 1.628 |
| Beta Downside | 1.253 |
| Drawdowns 3y | |
|---|---|
| Max DD | 92.77% |
| CAGR/Max DD | 0.93 |
Description: WGS GeneDx Holdings January 11, 2026
GeneDx Holdings Corp. (NASDAQ: WGS) is a U.S.-based genomics firm that delivers genetic testing services, concentrating on pediatric and rare-disease diagnostics through whole-exome and whole-genome sequencing. The company also offers data-information services and is building an AI-driven platform to automate next-generation sequencing (NGS) analysis, interpretation, and clinical reporting for rare diseases, hereditary risk, and oncology applications. GeneDx is headquartered in Stamford, Connecticut, and is classified under the Health Care Equipment sub-industry.
Key operating metrics that analysts watch include the company’s 2023 revenue of roughly $120 million, a year-over-year growth rate of ~15% driven by expanding rare-disease panels, and a gross margin hovering near 55%, reflecting the high-value nature of NGS services. The broader genomic-testing market is projected to expand at a CAGR of 12-14% through 2030, propelled by increasing newborn screening mandates, rising insurance reimbursement for hereditary testing, and accelerating adoption of AI-enhanced diagnostics that can lower per-sample costs.
For a deeper dive into GeneDx’s valuation dynamics and how its AI roadmap compares to peers, you may find it worthwhile to explore the analysis on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 2.08m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 17.80 > 1.0 |
| NWC/Revenue: 37.29% < 20% (prev 40.66%; Δ -3.38% < -1%) |
| CFO/TA 0.07 > 3% & CFO 33.2m > Net Income 2.08m |
| Net Debt (17.2m) to EBITDA (31.8m): 0.54 < 3 |
| Current Ratio: 2.71 > 1.5 & < 3 |
| Outstanding Shares: last quarter (28.8m) vs 12m ago 6.28% < -2% |
| Gross Margin: 69.65% > 18% (prev 0.59%; Δ 6905 % > 0.5%) |
| Asset Turnover: 89.10% > 50% (prev 65.36%; Δ 23.74% > 0%) |
| Interest Coverage Ratio: 2.91 > 6 (EBITDA TTM 31.8m / Interest Expense TTM 2.72m) |
Altman Z'' -13.89
| A: 0.30 (Total Current Assets 237.6m - Total Current Liabilities 87.6m) / Total Assets 493.9m |
| B: -2.75 (Retained Earnings -1.36b / Total Assets 493.9m) |
| C: 0.02 (EBIT TTM 7.92m / Avg Total Assets 451.4m) |
| D: -6.72 (Book Value of Equity -1.35b / Total Liabilities 201.6m) |
| Altman-Z'' Score: -13.89 = D |
Beneish M -2.85
| DSRI: 1.05 (Receivables 60.9m/38.5m, Revenue 402.2m/267.2m) |
| GMI: 0.85 (GM 69.65% / 59.48%) |
| AQI: 0.94 (AQ_t 0.38 / AQ_t-1 0.41) |
| SGI: 1.51 (Revenue 402.2m / 267.2m) |
| TATA: -0.06 (NI 2.08m - CFO 33.2m) / TA 493.9m) |
| Beneish M-Score: -2.85 (Cap -4..+1) = A |
What is the price of WGS shares?
Over the past week, the price has changed by -12.44%, over one month by -37.93%, over three months by -39.23% and over the past year by +35.58%.
Is WGS a buy, sell or hold?
- StrongBuy: 5
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the WGS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 170 | 101.7% |
| Analysts Target Price | 170 | 101.7% |
| ValueRay Target Price | 73.8 | -12.5% |
WGS Fundamental Data Overview February 04, 2026
P/E Forward = 82.6446
P/S = 7.1157
P/B = 9.5083
Revenue TTM = 402.2m USD
EBIT TTM = 7.92m USD
EBITDA TTM = 31.8m USD
Long Term Debt = 51.6m USD (from longTermDebt, last quarter)
Short Term Debt = 4.43m USD (from shortTermDebt, last quarter)
Debt = 113.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 17.2m USD (from netDebt column, last quarter)
Enterprise Value = 2.82b USD (2.86b + Debt 113.2m - CCE 155.1m)
Interest Coverage Ratio = 2.91 (Ebit TTM 7.92m / Interest Expense TTM 2.72m)
EV/FCF = 182.3x (Enterprise Value 2.82b / FCF TTM 15.5m)
FCF Yield = 0.55% (FCF TTM 15.5m / Enterprise Value 2.82b)
FCF Margin = 3.85% (FCF TTM 15.5m / Revenue TTM 402.2m)
Net Margin = 0.52% (Net Income TTM 2.08m / Revenue TTM 402.2m)
Gross Margin = 69.65% ((Revenue TTM 402.2m - Cost of Revenue TTM 122.1m) / Revenue TTM)
Gross Margin QoQ = 72.40% (prev 69.04%)
Tobins Q-Ratio = 5.71 (Enterprise Value 2.82b / Total Assets 493.9m)
Interest Expense / Debt = 0.50% (Interest Expense 562.0k / Debt 113.2m)
Taxrate = 21.0% (US default 21%)
NOPAT = 6.26m (EBIT 7.92m * (1 - 21.00%))
Current Ratio = 2.71 (Total Current Assets 237.6m / Total Current Liabilities 87.6m)
Debt / Equity = 0.39 (Debt 113.2m / totalStockholderEquity, last quarter 292.3m)
Debt / EBITDA = 0.54 (Net Debt 17.2m / EBITDA 31.8m)
Debt / FCF = 1.11 (Net Debt 17.2m / FCF TTM 15.5m)
Total Stockholder Equity = 268.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 0.46% (Net Income 2.08m / Total Assets 493.9m)
RoE = 0.78% (Net Income TTM 2.08m / Total Stockholder Equity 268.0m)
RoCE = 2.48% (EBIT 7.92m / Capital Employed (Equity 268.0m + L.T.Debt 51.6m))
RoIC = 1.96% (NOPAT 6.26m / Invested Capital 319.8m)
WACC = 11.47% (E(2.86b)/V(2.98b) * Re(11.91%) + D(113.2m)/V(2.98b) * Rd(0.50%) * (1-Tc(0.21)))
Discount Rate = 11.91% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 5.29%
[DCF Debug] Terminal Value 56.38% ; FCFF base≈15.5m ; Y1≈10.2m ; Y5≈4.63m
Fair Price DCF = 1.39 (EV 57.3m - Net Debt 17.2m = Equity 40.1m / Shares 28.9m; r=11.47% [WACC]; 5y FCF grow -40.0% → 2.90% )
[DCF Warning] FCF declining rapidly (-40.0%), DCF may be unreliable
EPS Correlation: 58.02 | EPS CAGR: 3.64% | SUE: -0.31 | # QB: 0
Revenue Correlation: 73.96 | Revenue CAGR: 20.62% | SUE: 1.93 | # QB: 7
EPS next Quarter (2026-03-31): EPS=-0.02 | Chg30d=-0.011 | Revisions Net=+0 | Analysts=4
EPS next Year (2026-12-31): EPS=0.63 | Chg30d=+0.207 | Revisions Net=+3 | Growth EPS=-54.7% | Growth Revenue=+27.0%